October 09, 2012

Genzyme to Present New Data from AUBAGIO and LEMTRADA Clinical Development Programs at ECTRIMS

- Depth and Breadth of data from the Genzyme MS Franchise Underscore Company’s Commitment to Addressing Unmet Needs of People Living with Multiple Sclerosis -

 

Genzyme to Present New Data from AUBAGIO and LEMTRADA Clinical Development Programs at ECTRIMS
- Depth and Breadth of data from the Genzyme MS Franchise Underscore Company’s Commitment to Addressing Unmet Needs of People Living with Multiple Sclerosis -

Paris, France – October 9, 2012 – Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today new data from Genzyme’s clinical development programs for AUBAGIO® (teriflunomide) and LEMTRADATM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.